Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 12/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.65 |
| ▸ | F3 | P13726 | 3/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | USP7 | Q93009 | 1/20 | 0.60 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.60 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.60 |
| ▸ | TOP2A | P11388 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4324523 | 1.00 | PTPN1 (0.68) | PTPN1ALOX5F3USP2LMNA | |
| SCHEMBL15132632 | 1.00 | PTPN1 (0.68) | PTPN1ALOX5F3USP2LMNA | |
| SCHEMBL30222071 | 1.00 | PTPN1 (0.68) | PTPN1ALOX5F3USP2LMNA | |
| SCHEMBL15883003 | 0.92 | PTPN1 (0.66) | PTPN1ALOX5F3USP2LMNA | |
| SCHEMBL13559844 | 0.92 | PTPN1 (0.66) | PTPN1ALOX5F3USP2LMNA | |
| Barringtogenol C SCHEMBL1049164 | 0.91 | PTPN1 (0.81) | PTPN1ALOX5F3USP2CYP3A4 | |
| Barringtogenol C SCHEMBL15132635 | 0.91 | PTPN1 (0.81) | PTPN1ALOX5F3USP2CYP3A4 | |
| Barringtogenol C SCHEMBL14871943 | 0.91 | PTPN1 (0.81) | PTPN1ALOX5F3USP2CYP3A4 | |
| SCHEMBL1046309 | 0.90 | PTPN1 (0.83) | PTPN1ALOX5F3USP2LMNA | |
| SCHEMBL30893653 | 0.90 | PTPN1 (0.83) | PTPN1ALOX5F3USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295800-A1 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | SAPREME TECH BV (NL) | 2025-09-25 | — | — | US | claimed |
| EP-4610278-A2 | TARGETED SAPONIN-NUCLEIC ACID CONJUGATES FOR TREATMENT OF MUSCLE WASTING DISORDERS | Sapreme Technologies B.V. (NL) | 2025-09-03 | — | — | EP | claimed |
| EP-4596052-A2 | THERAPEUTIC COMBINATION OF GALNAC-OLIGONUCLEOTIDE CONJUGATE AND SAPONIN, AND USES THEREOF | Sapreme Technologies B.V. (NL) | 2025-08-06 | — | — | EP | claimed |
| EP-4452331-B1 | TARGETED SAPONIN-NUCLEIC ACID CONJUGATES FOR TREATMENT OF MUSCLE WASTING DISORDERS | SAPREME TECH BV (NL) | 2025-08-06 | — | — | EP | claimed |
| EP-4591938-A2 | CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC | Sapreme Technologies B.V. (NL) | 2025-07-30 | — | — | EP | claimed |
| EP-4210760-B1 | CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC | SAPREME TECH BV (NL) | 2025-06-18 | — | — | EP | claimed |
| EP-4529953-A2 | CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC | Sapreme Technologies B.V. (NL) | 2025-04-02 | — | — | EP | claimed |
| US-20250082759-A1 | COMPOSITIONS COMPRISING THERAPEUTIC NUCLEIC ACID AND TARGETED SAPONIN FOR THE TREATMENT OF MUSCLE-WASTING DISORDERS | SAPREME TECHNOLOGIES B.V. (NL) | 2025-03-13 | — | — | US | claimed |
| US-20250057971-A1 | TARGETED SAPONIN-NUCLEIC ACID CONJUGATES FOR TREATMENT OF MUSCLE WASTING DISORDERS | SAPREME TECHNOLOGIES B.V. (NL) | 2025-02-20 | — | — | US | claimed |
| EP-4452325-A1 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | Sapreme Technologies B.V. (NL) | 2024-10-30 | — | — | EP | claimed |
| EP-4171641-A1 | CONJUGATE OF GALNAC AND SAPONIN, THERAPEUTIC COMPOSITION COMPRISING SAID CONJUGATE AND A GALNAC-OLIGONUCLEOTIDE CONJUGATE | Sapreme Technologies B.V. (NL) | 2023-05-03 | — | — | EP | claimed |
| EP-4171643-A1 | THERAPEUTIC COMBINATION OF GALNAC-OLIGONUCLEOTIDE CONJUGATE AND SAPONIN, AND USES THEREOF | Sapreme Technologies B.V. (NL) | 2023-05-03 | — | — | EP | claimed |
| EP-4171640-A1 | CONJUGATE OF SAPONIN AND SINGLE-DOMAIN ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING SAID CONJUGATE, THERAPEUTIC USE THEREOF | Sapreme Technologies B.V. (NL) | 2023-05-03 | — | — | EP | claimed |
| EP-4171639-A2 | SAPONIN DERIVATIVES FOR USE IN MEDICINE | Sapreme Technologies B.V. (NL) | 2023-05-03 | — | — | EP | claimed |
| EP-4171644-A2 | SAPONIN DERIVATIVES FOR USE IN MEDICINE | Sapreme Technologies B.V. (NL) | 2023-05-03 | — | — | EP | claimed |
| EP-4126060-A1 | COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE | Sapreme Technologies B.V. (NL) | 2023-02-08 | — | — | EP | claimed |
| EP-4117730-A1 | CONJUGATE OF SAPONIN AND SINGLE-DOMAIN ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING SAID CONJUGATE, THERAPEUTIC USE THEREOF | Sapreme Technologies B.V. (NL) | 2023-01-18 | — | — | EP | claimed |
| EP-4117731-A1 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | Sapreme Technologies B.V. (NL) | 2023-01-18 | — | — | EP | claimed |
| EP-4003427-A1 | SAPONIN DERIVATIVES WITH IMPROVED THERAPEUTIC WINDOW | SAPREME TECHNOLOGIES B.V. (NL) | 2022-06-01 | — | — | EP | claimed |
| WO-2022055351-A1 | CONJUGATE OF SAPONIN, OLIGONUCLEOTIDE AND GALNAC | SAPREME TECHNOLOGIES B.V. (NL) | 2022-03-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295800-A1 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | CYP46A1, HCCS, DHCR7 | PTPN1 485/4885ALOX5 1517/4885F3 704/4885 |
| US-20250082759-A1 | COMPOSITIONS COMPRISING THERAPEUTIC NUCLEIC ACID AND TARGETED SAPONIN FOR THE TREATMENT OF MUSCLE-WASTING DISORDERS | MUSK, TNNC1, PYGM | PTPN1 2705/4885ALOX5 4328/4885F3 4229/4885 |
| US-20250057971-A1 | TARGETED SAPONIN-NUCLEIC ACID CONJUGATES FOR TREATMENT OF MUSCLE WASTING DISORDERS | TNNC1, GYS1, PYGM | PTPN1 3135/4885ALOX5 4497/4885F3 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.